The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan ... NeoADAURA in the neoadjuvant setting and ADAURA 2 in the adjuvant setting – that, if positive ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

Trodelvy was the first Trop-2-directed ADC approved ... which is partnered with ADC powerhouse Daiichi Sankyo. Gilead will present third quarter earnings on November 6.

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

Daiichi Sankyo appears undervalued based on cash flows, trading at ¥4,869 against an estimated fair value of ¥7,851.18. Recent earnings growth of 55.5% and a forecasted annual profit increase of ...

Thank you for taking time out of your busy schedule to attend Daiichi Sankyo's Financial Results Presentation ... expenses increased by JPY 53.2 billion and research and development expenses ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize ... packages and approximately 2 billion tablets, which are then ...

New Delhi, The Delhi High Court on Tuesday ordered auctioning of the Fortis trademark in connection with the ₹3,500 crore arbitral award passed in favour of Japanese pharma major Daiichi Sankyo ...

The operator of the crippled Fukushima Daiichi nuclear power plant says a retrieval device has successfully grabbed nuclear fuel debris in the containment vessel of the No.2 reactor. Tokyo ...